A Phase 1/2 study of ATV-1601 in hereditary hemorrhagic telangiectasia (HHT)

Study Description

A study testing an investigational oral medication (ATV-1601) to treat moderate to severe hereditary hemorrhagic telangiectasia, a condition that causes abnormal blood vessel formation and bleeding

Study Details

Registry ID:

NCT07601425

Conditions:

Hereditary Hemorrhagic Telangiectasia (HHT), Osler Weber Rendu Disease

Phase:

Phase 1,Phase 2

Target Enrollment:

100 participants

Start Date:

July 27, 2026

Age Range:

18–999 years

Healthy Volunteers:

No

Study Locations (11 sites)

• Hospital Italiano de Buenos Aires
  Buenos AiresArgentina, Argentina
• Massachusetts General Hospital
  Boston, MassachusettsUnited States, United States
• University of North Carolina
  Chapel Hill, North CarolinaUnited States, United States
• Augusta University Medical Center
  Augusta, GeorgiaUnited States, United States
• Innovative Hematology
  Indianapolis, IndianaUnited States, United States
• Washington University in St. Louis
  St Louis, MissouriUnited States, United States
• Mayo Clinic
  Rochester, MinnesotaUnited States, United States
• Barrow Neurological Institute
  Phoenix, ArizonaUnited States, United States
• Arizona Pulmonary Specialists
  Phoenix, ArizonaUnited States, United States
• University of Utah Health Sciences Center
  Salt Lake City, UtahUnited States, United States
• University of California, San Diego
  San Diego, CaliforniaUnited States, United States

Interested in Participating?

Check your eligibility and learn more about this study on TrialScreen.

View full study details and check eligibility →